MGC Diagnostics is pleased to announce a global distribution agreement with Bedfont® Scientific Ltd.
MGC Diagnostics, a global medical technology company dedicated to cardiorespiratory health solutions and products focused on physician offices, laboratories, hospitals, and universities has partnered with UK med-tech company, Bedfont® Scientific Ltd., a world leader in breath analysis, whose portfolio includes the NObreath® fractional exhaled nitric oxide test monitor for use in the hospital or at remote locations.
Branded the FeNObreath®, MGC Diagnostics will leverage its cardiopulmonary products and diagnostic device experience by providing Fractional Exhaled Nitric Oxide (FeNO) testing to measure airway inflammation for the management and aid in diagnosis of conditions such as asthma.
“We are proud that our partnership with Bedfont® Scientific, Ltd. gives our customers access to proven and validated FeNO technology. Bedfont gives us the opportunity to bring a great product to our markets and to provide a simple and affordable solution to those looking for a FeNO monitor.” said Ralph Cook, Vice President of Global Marketing and Product Management of MGC Diagnostics.
The FeNObreath works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient. Interpreting FeNO levels aids in identifying patients who do/do not require ongoing treatment1 while also differentiating between allergic (eosinophilic) and non-allergic asthma2, and if used daily, FeNO measurements can help to predict and prevent exacerbations and attacks3.
“We’re excited to be working with MGC Diagnostics,” said Jason Smith, Managing Director at Bedfont® Scientific Ltd. “We are very impressed with their strong foothold in the respiratory market, their preceding reputation for product quality and customer support, and their commitment and enthusiasm to improving respiratory care. MGC Diagnostics is the perfect distribution partner to help us realise our goal of making FeNO monitoring more accessible globally.”
About MGC Diagnostics
MGC Diagnostics Corporation is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures, and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company’s products are sold in the United States through a direct sales force, and internationally through a combination of direct sales and Business Partners who target pulmonary and cardiac specialists in hospitals, clinics, universities, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.
About Bedfont Scientific Ltd
Established in 1976, Bedfont® Scientific Limited is a second-generation family company that has specialised in the design and manufacture of exhaled breath and gas monitoring instruments for medical applications, globally, for over 40 years. Bedfont® is revered as a pioneer in the breath analysis market with their products now available in over 76 countries across the world thanks to their unprecedented network of appointed distributors. Their aim is to continue innovating and improving health worldwide.
- Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
- Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 21 December 2021]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
- Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 21 December 2021]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990